Cargando…

Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide

Detalles Bibliográficos
Autores principales:	Canella, Alessandro, Nieves, Hector Cordero, Sborov, Douglas W., Cascione, Luciano, Radomska, Hanna S., Smith, Emily, Stiff, Andrew, Consiglio, Jessica, Caserta, Enrico, Rizzotto, Lara, Zanesi, Nicola, Stefano, Volinia, Kaur, Balveen, Mo, Xiaokui, Byrd, John C., Efebera, Yvonne A., Hofmeister, Craig C., Pichiorri, Flavia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519243/ https://www.ncbi.nlm.nih.gov/pubmed/37747363 http://dx.doi.org/10.18632/oncotarget.28515

Ejemplares similares

HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
por: Canella, Alessandro, et al.
Publicado: (2015)

Circulating miRNA markers show promise as new prognosticators for multiple myeloma
por: Rocci, A, et al.
Publicado: (2014)

Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis
por: Murahari, Sridhar, et al.
Publicado: (2017)

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide
por: Du, Li, et al.
Publicado: (2022)

In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
por: Pichiorri, Flavia, et al.
Publicado: (2013)

Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
por: Pichiorri, Flavia, et al.
Publicado: (2017)

AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition
por: Zhang, Mingming, et al.
Publicado: (2016)

Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo
por: Ghose, Jayeeta, et al.
Publicado: (2021)

AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma
por: Zhu, Yuxuan, et al.
Publicado: (2019)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P. G., et al.
Publicado: (2018)

On atmospheric $^{39}Ar$ and $^{42}Ar$ abundance
por: Cennini, P, et al.
Publicado: (1995)

Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing
por: Liva, Sophia, et al.
Publicado: (2021)

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
por: Sborov, Douglas W., et al.
Publicado: (2022)

Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma
por: Jaime-Ramirez, Alena C., et al.
Publicado: (2017)

The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo
por: Lucas, David M., et al.
Publicado: (2010)

Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment
por: Zhou, Maojun, et al.
Publicado: (2021)

LGG-42. Thromboembolic toxicity observed with concurrent trametinib and lenalidomide therapy
por: Chan, Priya, et al.
Publicado: (2022)

Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42()()
por: Henderson, Sally E., et al.
Publicado: (2016)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model
por: Motiwala, Tasneem, et al.
Publicado: (2014)

Down regulation of PSA by C/EBPα is associated with loss of AR expression and inhibition of PSA promoter activity in the LNCaP cell Line
por: Yin, Hong, et al.
Publicado: (2006)

MicroRNA Profiles Discriminate among Colon Cancer Metastasis
por: Drusco, Alessandra, et al.
Publicado: (2014)

Common Fragile Site Tumor Suppressor Genes and Corresponding Mouse Models of Cancer
por: Drusco, Alessandra, et al.
Publicado: (2011)

Lenalidomide-Associated ITP
por: Herold, Christina I., et al.
Publicado: (2011)

Human HMGA2 protein overexpressed in mice induces precursor T-cell lymphoblastic leukemia
por: Efanov, A, et al.
Publicado: (2014)

Dual inhibition of AKT‐mTOR and AR signaling by targeting HDAC3 in PTEN‐ or SPOP‐mutated prostate cancer
por: Yan, Yuqian, et al.
Publicado: (2018)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal
por: Geyer, Mark B., et al.
Publicado: (2023)

Lenalidomide and Chronic Lymphocytic Leukemia
por: González-Rodríguez, Ana Pilar, et al.
Publicado: (2013)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Hyperbilirubinemia following lenalidomide administration
por: Azmy, Veronica, et al.
Publicado: (2018)

Lenalidomide‐induced eosinophilic pneumonia
por: Toma, Andrew, et al.
Publicado: (2017)

Therapy of Angiosarcoma with Thalidomide and Lenalidomide
por: Mattes, M. Jules, et al.
Publicado: (2021)

Severe Lenalidomide-Associated Hyperbilirubinemia
por: Gildea, Daniel T, et al.
Publicado: (2023)

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2018)

Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas
por: Welling, D. Bradley, et al.
Publicado: (2021)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1dt4fmsasep4d7bt10k6auf4gf